Peptide finder

What are you trying to change?

Pick as many as you like. The number on each one is how many people it has been measured in across the whole archive. So you can see where the evidence is before you choose.

1. 01PlecanatidePeptideStrong. At least two finished studies in people, and at least 1,000 people who took it. 2 completed trials, 1,337 people given it.3 reported

   1,337 people2 studies

   • Plecanatide helped chronic constipation, and it helped roughly one extra person in fourteen. 1,337 adults took one of two doses or a dummy pill, and nobody involved knew which. About 20 in every hundred on either dose became lasting responders, against about 13 on the dummy. Both doses worked the same, so the higher...

     Therapeutic Advances in Gastroenterology, 2017 · 1,337 people

   • The drug works across most kinds of patient, with one gap. Researchers pooled two identical trials, 2,639 adults in all, and split the results by age, weight, race and sex. Both doses beat the dummy pill in nearly every group, including people over 65 and people who were not White. The exception was the higher dose in...

     Clinical and Translational Gastroenterology, 2023 · number of people not given

2. 02TrametinibSmall moleculeStrong. At least two finished studies in people, and at least 1,000 people who took it. 2 completed trials, 1,192 people given it.

   322 people1 study

   • In advanced melanoma with a BRAF mutation, trametinib on its own held the cancer back longer than chemotherapy and more people were alive at six months. Rash, diarrhoea and swelling were the common side effects. This is the trial that led to its approval as a single drug.

     The New England Journal of Medicine, 2012 · 322 people

3. 03MifepristoneSmall moleculeModerate. At least one finished study in people, and at least 100 people who took it. 2 completed trials, 320 people given it.4 reported

   270 people1 study

   • The other approved use. Mifepristone followed by misoprostol ended early pregnancies without surgery in nearly all of 270 women. Putting the second drug in the vagina worked better than swallowing it. Every woman got mifepristone. What was decided by chance was how the second drug was taken.

     The New England Journal of Medicine, 1995 · 270 people

4. 04FGF21BiologicModerate. At least one finished study in people, and at least 100 people who took it. 2 completed trials, 350 people given it.4 reported

   222 people1 study

   • A lab-built version of FGF21 healed liver scarring in a mid-sized study. 222 people with fatty liver disease and moderate to advanced scarring got one of three doses or a dummy shot, for 24 weeks. Scarring improved without the disease getting worse in 7% of the dummy group, against 22% to 27% on the drug. The disease...

     New England Journal of Medicine, 2023 · 222 people

5. 05LarazotidePeptideModerate. At least one finished study in people, and at least 100 people who took it. 2 completed trials, 526 people given it.

   184 people1 study1 found nothing

   • found nothingLarazotide reduced symptoms during a deliberate gluten challenge, but missed the thing it was designed to fix. A hundred and eighty-four people with coeliac disease ate gluten on purpose while taking the drug or a dummy. On 1 mg, symptoms were milder and the rise in a coeliac antibody was blunted. The leakiness of the...

     Alimentary Pharmacology and Therapeutics, 2013 · 184 people

6. 06IpamorelinPeptideModerate. At least one finished study in people, and at least 100 people who took it. 2 completed trials, 157 people given it.9 reported

   117 people1 study

   • Ipamorelin was tested properly after bowel surgery and it did not work. 117 people who had had part of the bowel removed got ipamorelin into a vein or a dummy drip. Nobody involved knew which. The aim was to get them eating sooner. On ipamorelin the first meal that stayed down came about 25 hours after surgery,...

     International Journal of Colorectal Disease, 2014 · 117 people

7. 07Tesamorelin / IpamorelinBlendStrong. At least two finished studies in people, and at least 1,000 people who took it. 5 completed trials, 1,507 people given it.9 reported

   117 people1 study

   • Ipamorelin has been tested in people once, and it failed. A hundred and seventeen patients who had just had bowel surgery were given it into a vein or a dummy. On average they managed a meal sooner, 25.3 hours against 32.6, but the gap was too small to separate from chance. The drug was well tolerated. This is the...

     International Journal of Colorectal Disease, 2014 · 117 people

8. 08Sermorelin with ipamorelinBlendModerate. At least one finished study in people, and at least 100 people who took it. 1 completed trial, 117 people given it.8 reported

   117 people1 study

   • Ipamorelin has been tested properly in people exactly once, and it was for a gut problem after surgery. 117 adults having part of the bowel removed got either ipamorelin into a vein twice a day or a dummy drip, by chance. They got it from the day after surgery until they went home or a week passed. The study watched...

     International Journal of Colorectal Disease, 2014 · 117 people

9. 09CJC-1295 with ipamorelin and GHRP-2BlendModerate. At least one finished study in people, and at least 100 people who took it. 2 completed trials, 117 people given it.5 reported

   117 people1 study

   • Ipamorelin has been through one real study in people, and it was about recovery after bowel surgery. 117 patients got either ipamorelin into a vein twice a day or a dummy drip, by chance. It was safe. The study measured how soon patients could handle a solid meal. That is the whole proper record for this peptide in...

     International Journal of Colorectal Disease, 2014 · 117 people

10. 10MK-677 with ipamorelinBlendModerate. At least one finished study in people, and at least 100 people who took it. 2 completed trials, 182 people given it.7 reported

    117 people1 study

    • Ipamorelin has one proper study in people, and it was done after bowel surgery. 117 adults got either ipamorelin into a vein twice a day or a dummy drip, by chance. The study measured how quickly they could eat a solid meal again. Safety was the real finding. It is still the only proper test of this peptide in people....

      International Journal of Colorectal Disease, 2014 · 117 people

11. 11MIB-626SupplementModerate. At least one finished study in people, and at least 100 people who took it. 4 completed trials, 107 people given it.1 reported

    65 people1 study

    • This trial suggests oral NMN may work through gut bacteria rather than directly, which would apply to this product too. 65 healthy adults took one of three NAD boosters for two weeks, and everyone knew what they were taking. NMN and nicotinamide riboside both raised NAD in the blood. Plain nicotinamide did not keep it...

      Nature Metabolism, 2026 · 65 people

12. 12CotadutidePeptideStrong. At least two finished studies in people, and at least 1,000 people who took it. 6 completed trials, 1,221 people given it.

    65 people1 study

    • An early trial showed cotadutide blunts the blood sugar spike after a meal, and takes off some weight. 65 adults with diabetes and extra weight took it daily for seven weeks, or a dummy. After meals, blood sugar rose about a fifth less, while it climbed on the dummy. Weight fell about three and a half percent, against...

      Journal of Clinical Endocrinology and Metabolism, 2020 · 65 people

13. 13InulinSupplementLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, 39 people given it.6 reported

    39 people1 study

    • Inulin made constipation better, in a small test that ran into a design problem. 39 adults with long-running constipation took 12 g of chicory inulin daily for four weeks and a dummy for four more. Each person tried both in turn without knowing which. Bowel frequency, belly symptoms and quality of life all improved on...

      BMC Gastroenterology, 2025 · 39 people

14. 14TERN-601Small moleculeLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, 3 people given it.3 reported

    3 people1 study

    • TERN-601 caused weight loss, then ended its own program with liver damage. There were two studies, one for 28 days and one for 12 weeks, both against a dummy pill. In the first, every dose led to more weight loss than the dummy pill, with less hunger and slower stomach emptying. In the second, doses of 500 mg and up...

      Obesity, 2026 · 3 people

15. 15GLP-1PeptideLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, 8 people given it.1 reported

    number of people not given1 study

    • The hormone your own gut makes does what the drugs built from it do, only briefly. Adults with obesity injected native GLP-1 before meals for five days, and also spent a period on a dummy, with nobody knowing which. Food eaten at each meal fell by about 15 percent and they lost 0.55 kg. Food leaving the stomach more...

      British Journal of Nutrition, 2004 · number of people not given

16. 16PegcetacoplanPeptideStrong. At least two finished studies in people, and at least 1,000 people who took it. 3 completed trials, 1,258 people given it.3 reported

    number of people not given1 study

    • Pegcetacoplan beat the existing drug in people whose blood disease it was failing to control. 80 adults who were still anaemic on eculizumab were switched to one drug or the other, and everyone knew which. Haemoglobin rose clearly more on pegcetacoplan. 35 of 41 on it avoided a transfusion, against 6 of 39 on...

      New England Journal of Medicine, 2021 · number of people not given

17. 17Semaglutide with B12BlendLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, none stating how many people.7 reported

    number of people not given1 study

    • Semaglutide caused large, well documented weight loss, and this is the study that showed it. Adults took a weekly 2.4 mg shot or a dummy shot for about 16 months. Average body weight fell 14.9% on the drug and 2.4% on the dummy, a gap of about 12 points. Half the drug group lost at least a sixth of their body weight,...

      New England Journal of Medicine, 2021 · number of people not given

18. 18BI 1820237PeptidePreliminary. Studied in people, but no published study has had people take it. 2 human studies where nobody was given it.

    95 people1 study1 found nothing

    • found nothingThis first test in people was about safety, and the drug made a lot of them sick. 95 otherwise healthy men carrying extra weight were given single rising doses, some with a low dose of liraglutide alongside. Drug-related side effects, mostly stomach and bowel, hit about 39% in the first two parts and about 31% in the...

      Diabetes, Obesity and Metabolism, 2025 · 95 people

19. 19BGM0504PeptideLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, 64 people given it.

    40 people1 study

    • Healthy volunteers, and the weight figures belong to healthy volunteers. 40 healthy Chinese people took a single 2.5 mg dose, then weekly doses rising to 5, 10 and 15 mg. The amount in the blood rose in step with the dose across that range. Weight fell 3.24, 6.26, 7.09 and 8.30 percent at the four doses. Vomiting,...

      Diabetes, Obesity and Metabolism, 2025 · 40 people

20. 20KPVPeptideAnimal or lab only. Only animal or lab studies on this page. No study in people yet. 2 animal studies, no human study.6 reported

    number of people not given0 studies

    • In mice with colitis, KPV carried in tiny particles sped up healing of the gut lining and lowered a swelling signal called TNF-alpha.

      Molecular Therapy, 2017 · number of people not given

21. 21Methylene BlueSmall moleculeLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, 26 people given it.7 reported

    number of people not given0 studies
22. 22MetforminSmall moleculeModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 489 people given it.6 reported

    number of people not given0 studies
23. 23Tirzepatide with B12BlendLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, none stating how many people.6 reported

    number of people not given0 studies
24. 24Semaglutide with cagrilintideBlendStrong. At least two finished studies in people, and at least 1,000 people who took it. 4 completed trials, 4,219 people given it.6 reported

    number of people not given0 studies